Mercer Global Advisors
SGMT icon

Mercer Global Advisors’s Sagimet Biosciences SGMT Stock Holding History

Mercer Global Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Buy
+2,128
New +$14.5K ﹤0.01% 4917

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Mercer Global Advisors's SGMT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 2,128 shares worth $16.4K. The stake represents ﹤0.01% of the portfolio and ranks #4917 among its holdings.

80 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Mercer Global Advisors held 2,128 shares of Sagimet Biosciences worth $16.4K as of Q2 2026.
  • Sagimet Biosciences was a new Mercer Global Advisors position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4917 holding.
  • 80 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.